Status:
COMPLETED
Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
35-70 years
Brief Summary
Type 2 diabetes is the predominant type of diabetes. Because a quiet evolution, it is difficult to have a rapid diagnose. A better knowledge about pathophysiological mechanisms at the origin of type 2...
Eligibility Criteria
Inclusion
- Coloscopy indication
- Capacity to give a written informed consent
Exclusion
- Type 1 diabetes
- Severe renal failure
- Antecedent of liver fibrosis and/or liver failure
- Antecedent of inflammatory bowel disease, lymphocyte colitis, celiac disease or colon cancer
- Antecedent of obesity surgery or of total colectomy
- Antecedent of documented intestinal ischaemia
- Acute infection the week before the inclusion
- Congenital of acquired immune deficiency
- Chronic viral infection
- Antibiotic of probiotic the month before the coloscopy
- Pregnancy
- Patients participating to another research with an exclusion period
- Patients under guardianship
Key Trial Info
Start Date :
December 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 4 2021
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT02811575
Start Date
December 1 2016
End Date
March 4 2021
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Toulouse
Toulouse, France, 31059